mRNA

#Biotherapeutics #Cardiovascular disease #Clinical trials #mRNA #Therapeutics

Positive data from study of siRNA in iron-loading anaemia conditions

Silence Therapeutics and Nasdaq have announced positive topline data from the GEMINI Phase I study of its wholly owned product candidate, SLN124, in healthy volunteers. SLN124, an siRNA which targets TMPRSS6, is in development for the treatment of iron-loading anaemia conditions, thalassemia and myelodysplastic syndrome (MDS). The GEMINI Phase I,… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines #mRNA #Vaccines

CureVac GSK Covid-19 vaccine candidate shows high immunogenicity

CureVac, in collaboration with GSK, has announced that its second-generation Covid-19 vaccine candidate, CV2CoV, induces high levels of antigen production as well as strong and dose-dependent immune responses in vaccinated animals. CV2CoV is a co-development between CureVac and GSK and is based on a new mRNA backbone, which differs from… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA #Vaccines

Moderna invests to increase global supply for Covid-19 vaccine

Moderna is to increase supply at its manufacturing facilities, which it expects will increase global 2022 capacity to up to 3 billion doses of its Covid-19 vaccine. This will depend upon the mix between the authorised Moderna Covid-19 vaccine at the 100 μg dose level and potentially lower… Read More

#News

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #mRNA #Pfizer #Vaccines

Evonik delivers first lipids to BioNTech ahead of schedule

Chemical specialist Evonik is helping to accelerate the production of the Covid-19 vaccine from Pfizer-BioNTech by suppling an essential component. Evonik is delivering first batches of urgently needed lipids for the mRNA-based vaccine to BioNTech months earlier than anticipated. Specialists at Evonik’s Hanau site set up the lipid production in… Read More

#Covid-19 #News

#Clinical trial #Covid-19 #Immunology / Virology & Vaccines #mRNA #Vaccines

New study provides global analysis of Covid-19 vaccines

A new study by Novateur Ventures provides a comparative analysis of twelve Covid-19 vaccines that had initiated or announced the Phase III clinical trial stage by early November 2020. The study highlights the early successes, as well as the hurdles and barriers yet to be overcome for ending the global… Read More

#Covid-19 #News

#Biopharmaceutical #Drug development #Drug discovery #mRNA

Evotec and Takeda enter RNA targeting drug discovery alliance

Evotec has entered into a multi-RNA target alliance with Takeda Pharmaceutical with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches. Evotec and Takeda will jointly identify and develop small molecules targeting a range of… Read More

#News

#Biotechnology #Cancer research #Immunology / Virology & Vaccines #Immunotherapy #mRNA

Consortium awarded EU Commission TIGER Grant of €6.9 million

eTheRNA Immunotherapies, a clinical-stage company developing mRNA-based immunotherapies as off-the-shelf products for the treatment of cancer and infectious diseases, has announced the award of a TIGER grant of €6.9 million from the EU commission. The grant was awarded to a consortium led by eTheRNA and will be used to accelerate the development of… Read More

#Cancer Research #News

#Covid-19 #Drug delivery #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna starts vaccine trials on babies and children

Moderna has announced that the first participants have been dosed in the Phase II/II study, called the KidCOVE study, of mRNA-1273, the company’s vaccine candidate against COVID-19, in children ages 6 months to less than 12 years. The study is being conducted in collaboration with the National Institute of Allergy and… Read More

#Covid-19 #Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna doses first patients for its next generation COVID-19 vaccine

Moderna has announced that the first participants have been dosed in the Phase I study of mRNA-1283, the company’s next generation COVID-19 vaccine candidate. mRNA-1283 is being developed as a potential refrigerator stable mRNA vaccine that will facilitate easier distribution and administration by healthcare providers Stéphane Bancel, Chief Executive Officer… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Clinical trial #Covid-19 #Immunology / Virology & Vaccines #mRNA

Sanofi and Translate Bio begin clinical trial of COVID-19 vaccine

Sanofi Pasteurand Translate Bio, a clinical-stage mRNA therapeutics company, have announced the start of the Phase I/II clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2. The companies expect interim results from this trial in the third quarter of 2021. Thomas Triomphe, Executive Vice President and Global Head of… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines #mRNA

UK government invests £5m into Covid-19 variant vaccines

Budget Chancellor Rishi Sunak announced a £5 million investment in CPI to develop an mRNA ‘vaccine library’, as part of the government’s vaccines support package. The vaccine library will form the basis of a rapid response facility, enabling mRNA vaccines to be developed to help protect against new variants of… Read More

#News #Trending News

#Immunology / Virology & Vaccines #Life sciences #mRNA #Pharmaceutical

What the UK Budget means for the pharma sector: industry reaction

By Lu Rahman In his 2021 Budget, UK Chancellor of the Exchequer, Rishi Sunak, announced a range of measures designed to benefit UK science, business and technology. These included tax breaks for firms to designed to ‘unlock’ £20bn worth of business investment; incentives for companies to take on apprentices; allowing… Read More

#Editor's Choice #News #Trending News

#Cell and gene therapy #Immunology / Virology & Vaccines #mRNA

Evonik strengthens strategic partnership with BioNTech on COVID-19 vaccine

Evonik is investing in the short-term expansion of its specialty lipids production which are essential for mRNA-based COVID-19 vaccines. Commercial lipid quantities are to be produced at Evonik’s Hanau and Dossenheim sites in Germany as early as the second half of 2021 as part of a strategic partnership with vaccine… Read More

#Covid-19 #Editor's Choice #News

#Clinical trials #mRNA #Research & development

Clinical trials investigate treatment for diabetic eye disease

A new approach to treating one of the leading causes of blindness among patients with diabetes is being tested in clinical trials which begin this month. The trial involves 48 patient volunteers with diabetic macular oedema (DMO), a disease where blood vessels leak fluid into the retina. It is the… Read More

#Editor's Choice #News